Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $522.40, with a market capitalization of 132.41B. The stock trades at a price-to-earnings (P/E) ratio of 30.04.
On 2026-09-24, Vertex Pharmaceuticals(VRTX) stock moved within a range of $515.30 to $524.01. With shares now at $522.40, the stock is trading +1.4% above its intraday low and -0.3% below the session's peak.
Trading activity shows a volume of 41.21K, compared to an average daily volume of 1.08M.
The stock's 52-week range extends from a low of $374.17 to a high of $560.25.
The stock's 52-week range extends from a low of $374.17 to a high of $560.25.
VRTX News
Key Points CRISPR Therapeutics is transitioning into a commercial-stage company with its pioneering gene-editing treatment, CASGEVY. Vertex Pharmaceuticals ma...
Advertisement Vertex Pharmaceuticals stock moves on inaxaplin kidney data Vertex Pharmaceuticals (VRTX) drew fresh attention after reporting Phase 2b AMPLIFIE...
Vertex Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Salveen Richter from Goldman Sachs maintained a...
Analyst ratings
77%
of 35 ratingsMore VRTX News
Vertex Pharmaceuticals (NasdaqGS:VRTX) reported positive Phase 2b results for inaxaplin in APOL1-mediated kidney disease in people with type 2 diabetes. The Ph...
Technology The Surprise That Sent Vertex — And Its Chief Rival — Soaring Licensing Vertex stock popped Tuesday — while shares of rival Maze Therapeutics (MAZE)...
10:23 EDT Maze jumps 25% to $27.99 after Vertex kidney disease data Published first on TheFly – the ultimate source for real-time, market-moving breaking finan...
The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidne...
Key Points Vertex Pharmaceuticals has declined meaningfully from its most recent high. The company has several catalysts that could jolt the stock over the ne...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.